Weight loss Available in NZ = Liraglutide high dose (Saxenda, daily injection) Self-funding needed ($500-600/month) Not available in NZ = Semaglutide (Ozempic, Wegovy) or Tirzepatide (Mounjaro), as of May 2023 Side effects, particularly upper gastrointestinal, are common with GLP-1 agonist initiation
Quad-agonist designs that add amylin receptor engagement are in preclinical development
The needles are tiny, 30 or 31 gauge, thinner than a standard sewing needle
This may be, at least partially, responsible for the clinical benefits observed in the treatment of osteoarthritis, rheumatoid arthritis and fibromyalgia with SAM-e
It helps reduce the appearance of fine lines and wrinkles and promotes smoother, more youthful-looking skin
Phillipe OBrien was an employee of Eli Lilly and Company at the time of submission